Beta-thalassemia major is a hereditary, transfusion-dependent blood disorder in which repeated red blood cell transfusions cause progressive systemic iron accumulation, potentially affecting cardiac function. The objective of this study was to assess the correlation between serum ferritin levels and left ventricular ejection fraction (LVEF) in children with thalassemia major. This cross-sectional study was conducted in the Department of Pediatrics, Holy Family Hospital, Rawalpindi, and included 120 children aged 5–18 years who had undergone more than 10 blood transfusions and were receiving iron chelation therapy. Serum ferritin concentrations were measured using a standardized automated immunoassay, and LVEF was evaluated by transthoracic echocardiography. The mean age was 11.3 ± 3.6 years, and 67 participants (55.8%) were male. The median serum ferritin concentration was 3185 ng/mL (interquartile range: 2240–4410 ng/mL), whereas the mean LVEF was 58.1 ± 6.4%. A statistically significant, weak inverse correlation was observed between serum ferritin and LVEF (r = −0.211, p = 0.021). Mean LVEF declined across increasing ferritin categories, from 60.6 ± 5.3% in children with ferritin <2000 ng/mL to 56.0 ± 6.8% in children with ferritin ≥4000 ng/mL (p = 0.010). These findings indicate an association between higher serum ferritin concentrations and lower LVEF in this pediatric clinical population; they do not establish a causal relationship or directly demonstrate cardiac iron deposition. Regular monitoring of iron burden alongside clinical and cardiac assessment may support the identification of children requiring further evaluation and appropriate review of chelation therapy.
Beta-thalassemia major is a hereditary, transfusion-dependent blood disorder in which repeated red blood cell transfusions cause progressive systemic iron accumulation, potentially affecting cardiac function. The objective of this study was to assess the correlation between serum ferritin levels and left ventricular ejection fraction (LVEF) in children with thalassemia major. This cross-sectional study was conducted in the Department of Pediatrics, Holy Family Hospital, Rawalpindi, and included 120 children aged 5–18 years who had undergone more than 10 blood transfusions and were receiving iron chelation therapy. Serum ferritin concentrations were measured using a standardized automated immunoassay, and LVEF was evaluated by transthoracic echocardiography. The mean age was 11.3 ± 3.6 years, and 67 participants (55.8%) were male. The median serum ferritin concentration was 3185 ng/mL (interquartile range: 2240–4410 ng/mL), whereas the mean LVEF was 58.1 ± 6.4%. A statistically significant, weak inverse correlation was observed between serum ferritin and LVEF (r = −0.211, p = 0.021). Mean LVEF declined across increasing ferritin categories, from 60.6 ± 5.3% in children with ferritin <2000 ng/mL to 56.0 ± 6.8% in children with ferritin ≥4000 ng/mL (p = 0.010). These findings indicate an association between higher serum ferritin concentrations and lower LVEF in this pediatric clinical population; they do not establish a causal relationship or directly demonstrate cardiac iron deposition. Regular monitoring of iron burden alongside clinical and cardiac assessment may support the identification of children requiring further evaluation and appropriate review of chelation therapy.